BERWYN, PA — Virpax® Pharmaceuticals, Inc. announced it has regained compliance with Nasdaq’s minimum bid price requirement as of July 24, 2024. This achievement follows a formal notice from Nasdaq’s Listing Qualifications staff.
To meet the compliance criteria set by Nasdaq Listing Rule 5550(a)(2), Virpax’s common shares needed to close at a minimum bid price of $1.00 or higher for at least 10 consecutive business days. The company met this requirement on July 19, 2024.
This compliance ensures that Virpax remains listed on The Nasdaq Stock Market, closing this listing matter.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.